News for Arbutus Biopharma Corporation (ABUS)

Published at

Mar 3, 2025 4:00 PM

by gurufocus.com

positive

positive

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with

MRNA.MX MRNA M1RN34.SA ABUS 0SGC.L 0A45.L

Read more →
Published at

Mar 3, 2025 3:34 PM

by manilatimes.net

mixed

mixed

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

**media[555746]**

ABUS 0SGC.L MRNA.MX MRNA M1RN34.SA 0A45.L

Read more →
Published at

Mar 3, 2025 3:34 PM

by manilatimes.net

mixed

mixed

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

**media[555742]**

ABUS 0SGC.L MRNA.MX MRNA M1RN34.SA 0A45.L

Read more →
Published at

Feb 25, 2025 1:00 PM

by gurufocus.com

positive

positive

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS) (”Arbutus” or the ”Company”), a clinical-stage biopharmaceut

ABUS 0SGC.L

Read more →
Published at

Feb 23, 2025 3:34 AM

by gurufocus.com

positive

positive

Whitefort Capital Management, LP Increases Stake in Arbutus Biopharma Corp

Transaction Overview On February 20, 2025, Whitefort Capital Management, LP (Trades, Portfolio) executed a strategic stock transaction involving Arbutus Biophar

LQDA GNW.MX GNW CDZI ABUS 0HS4.L

Read more →
Published at

Feb 12, 2025 3:24 PM

by insidermonkey.com

mixed

mixed

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Arbutus Biopharma Corp.

ABUS MRNA

Read more →
Published at

Feb 11, 2025 7:42 PM

by insidermonkey.com

mixed

mixed

10 Best Nasdaq Stocks Under $5 to Buy

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.

EVGO ABUS MRNA

Read more →
Published at

Jan 30, 2025 9:40 PM

by seekingalpha.com

mixed

mixed

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. (undefined:ABUS)

Chris DeMuth, Jr. shares what's special about Arbutus, Burford Capital, and Cadiz and why an M&A boom is coming.

CAPD.L BUR.L BUR ABUS 0SGC.L CDZI

Read more →
Published at

Jan 13, 2025 1:47 PM

by manilatimes.net

positive

positive

Arbutus Provides 2025 Corporate and Financial Update

**media[513454]**

MRNA ABUS 0SGC.L

Read more →
Published at

Jan 13, 2025 1:43 PM

by seekingalpha.com

positive

positive

Arbutus expects to significantly reduce its net cash burn in 2025

Arbutus Biopharma announces 2025 objectives & financial update. Cash balance, reduced net cash burn, Phase 2b clinical trial initiation.

ABUS

Read more →
Published at

Jan 13, 2025 1:34 PM

by financialpost.com

positive

positive

Arbutus Provides 2025 Corporate and Financial Update

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon

MRNA ABUS 0SGC.L

Read more →
Published at

Jan 7, 2025 1:56 PM

by seekingalpha.com

positive

positive

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development (NASDAQ:ABUS)

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

ABUS

Read more →
Published at

Dec 3, 2024 3:00 PM

by gurufocus.com

positive

positive

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Whitefort Capital Management, LP (together with its affiliates, ”Whitefort Capital,” ”us” or ”we”), which is a long-term investor and the third lar

PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE MRNA.MX MRNA M1RN34.SA FRGAP BNTXN.MX BNTX ABUS 0SGC.L 0A45.L 0A3M.L

Read more →
Published at

Nov 26, 2024 2:00 PM

by gurufocus.com

positive

positive

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS), (”Arbutus” or the ”Company”), a clinical-stage biopharmaceut

ABUS 0SGC.L

Read more →
Published at

Nov 26, 2024 1:41 PM

by manilatimes.net

positive

positive

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

**media[476552]**

ABUS 0SGC.L

Read more →
Published at

Nov 15, 2024 5:04 PM

by investing.com

positive

positive

New trial shows promise for chronic hepatitis B treatment By Investing.com

New trial shows promise for chronic hepatitis B treatment

ABUS 0SGC.L

Read more →
Published at

Nov 15, 2024 5:03 PM

by financialpost.com

neutral

neutral

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial

ABUS 0SGC.L

Read more →
Published at

Nov 15, 2024 5:02 PM

by financialpost.com

positive

positive

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts asse…

ABUS 0SGC.L

Read more →
Published at

Nov 6, 2024 8:52 PM

by seekingalpha.com

positive

positive

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ETCompany ParticipantsLisa Caperelli - VP, Investor...

ABUS 0SGC.L

Read more →
Published at

Mar 20, 2024 1:16 PM

by marketscreener.com

positive

positive

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, March 20, 2024 -- Barinthus Biotherapeutics plc , formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the...

VACC AZN ABUS 0SGC.L

Read more →